The Melanoma Network of Canada (MNC) is gathering information from patients diagnosed with cutaneous Squamous Cell Carcinoma (cSCC) to help prepare a group submission to the pan-Canadian Oncology Drug Review (pCODR) on the experiences and opinions of patients and their caregivers for a new treatment therapy being proposed for patients. The drug under review is cemiplimab (Libtayo) which is an anti-pd1 immunotherapy indicated for the treatment of patients with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation.
Cutaneous squamous cell carcinoma (cSCC), is one of the most common types of skin cancer and is generally treated through topical aids, surgery or radiation. However, in certain cases, the cancer can spread and become life threatening. A drug review is imminent to assess whether provinces should fund this new breakthrough immunotherapy cemiplimab (Libtayo) for locally advanced or metastatic cSCC patients.
If you are a patient or caregiver your point of view will make a real difference and help inform decision making for (cSCC) patients in Canada!
Please note this link will take you to our Survey Monkey Webpage. It may take a moment to load.
Not Ready to Take the Survey?
Sign up for a friendly email reminder. You can unsubscribe at any time.
cutaneous Squamous Cell Carcinoma (cSCC) Patient Forum
Ask questions or learn from others. Join our online patient community by visiting MNC cSCC forum